1 Min Read
NEW YORK, Jan 21 (Reuters) - CytRx Corp : * Up 8.5 percent to $7.64 premarket; gets FDA OK to extend aldoxorubicin dosing cycles in late-stage trial for soft tissue sarcomas
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.